Bionano Genomics Inc (BNGO) - Net Assets
Based on the latest financial reports, Bionano Genomics Inc (BNGO) has net assets worth $44.42 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($73.58 Million) and total liabilities ($29.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BNGO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $44.42 Million |
| % of Total Assets | 60.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -86.82% |
| 10-Year Change | N/A |
| Growth Volatility | 409.35 |
Bionano Genomics Inc - Net Assets Trend (2016–2025)
This chart illustrates how Bionano Genomics Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Bionano Genomics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Bionano Genomics Inc (2016–2025)
The table below shows the annual net assets of Bionano Genomics Inc from 2016 to 2025. For live valuation and market cap data, see BNGO market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $44.42 Million | +25.58% |
| 2024-12-31 | $35.38 Million | -63.21% |
| 2023-12-31 | $96.16 Million | -61.44% |
| 2022-12-31 | $249.40 Million | -26.02% |
| 2021-12-31 | $337.12 Million | +860.94% |
| 2020-12-31 | $35.08 Million | +870.81% |
| 2019-12-31 | $3.61 Million | -64.35% |
| 2018-12-31 | $10.14 Million | +120.18% |
| 2017-12-31 | $-50.23 Million | -84.26% |
| 2016-12-31 | $-27.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bionano Genomics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68871932800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $17.00K | 0.04% |
| Other Components | $764.03 Million | 1719.85% |
| Total Equity | $44.42 Million | 100.00% |
Bionano Genomics Inc Competitors by Market Cap
The table below lists competitors of Bionano Genomics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NETUM GROUP OYJ
F:79J
|
$12.76 Million |
|
Effnetplattformen Holding AB
ST:EFFH
|
$12.77 Million |
|
Barunson Entertainment & Arts Corporation
KQ:035620
|
$12.77 Million |
|
Asia Sejahtera Mina Tbk
JK:AGAR
|
$12.77 Million |
|
Gold By Gold
PA:ALGLD
|
$12.74 Million |
|
Theriva Biologics Inc.
NYSE MKT:TOVX
|
$12.74 Million |
|
Dgenx Co. Ltd
KQ:113810
|
$12.74 Million |
|
Intraco Penta Tbk
JK:INTA
|
$12.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bionano Genomics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,375,000 to 44,424,000, a change of 9,049,000 (25.6%).
- Net loss of 26,395,000 reduced equity.
- New share issuances of 31,098,000 increased equity.
- Other comprehensive income decreased equity by 10,000.
- Other factors increased equity by 4,356,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.39 Million | -59.42% |
| Share Issuances | $31.10 Million | +70.0% |
| Other Comprehensive Income | $-10.00K | -0.02% |
| Other Changes | $4.36 Million | +9.81% |
| Total Change | $- | 25.58% |
Book Value vs Market Value Analysis
This analysis compares Bionano Genomics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-52.15 | $1.15 | x |
| 2017-12-31 | $-185.95 | $1.15 | x |
| 2018-12-31 | $50555.31 | $1.15 | x |
| 2019-12-31 | $8515.49 | $1.15 | x |
| 2020-12-31 | $3.37 | $1.15 | x |
| 2021-12-31 | $716.46 | $1.15 | x |
| 2022-12-31 | $507.26 | $1.15 | x |
| 2023-12-31 | $165.63 | $1.15 | x |
| 2024-12-31 | $18.59 | $1.15 | x |
| 2025-12-31 | $8.16 | $1.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bionano Genomics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -92.59%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.66x
- Recent ROE (-59.42%) is above the historical average (-181.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -277.48% | 0.46x | 0.00x | $-16.12 Million |
| 2017 | 0.00% | -245.82% | 0.94x | 0.00x | $-18.34 Million |
| 2018 | -182.46% | -154.13% | 0.48x | 2.45x | $-19.51 Million |
| 2019 | -825.63% | -294.55% | 0.34x | 8.36x | $-30.20 Million |
| 2020 | -117.25% | -483.78% | 0.14x | 1.72x | $-44.64 Million |
| 2021 | -21.49% | -402.84% | 0.05x | 1.12x | $-106.15 Million |
| 2022 | -53.17% | -476.93% | 0.09x | 1.23x | $-157.54 Million |
| 2023 | -241.78% | -643.74% | 0.17x | 2.23x | $-242.11 Million |
| 2024 | -316.66% | -363.98% | 0.40x | 2.17x | $-115.55 Million |
| 2025 | -59.42% | -92.59% | 0.39x | 1.66x | $-30.84 Million |
Industry Comparison
This section compares Bionano Genomics Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,396,254,507
- Average return on equity (ROE) among peers: -62.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bionano Genomics Inc (BNGO) | $44.42 Million | 0.00% | 0.66x | $12.76 Million |
| Akoya Biosciences Inc (AKYA) | $53.77 Million | -117.77% | 2.35x | $64.44 Million |
| Align Technology Inc (ALGN) | $218.54 Million | 36.60% | 0.28x | $12.09 Billion |
| AngioDynamics Inc (ANGO) | $372.19 Million | 2.67% | 0.10x | $447.90 Million |
| AptarGroup Inc (ATR) | $1.38 Billion | 11.78% | 0.68x | $7.66 Billion |
| AtriCure Inc (ATRC) | $161.17 Million | -16.69% | 0.66x | $1.38 Billion |
| Avinger Inc (AVGR) | $15.59 Million | -303.70% | 2.47x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $902.36 Million |
| Avantor Inc (AVTR) | $2.46 Billion | 1.54% | 2.97x | $5.44 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.07 Billion |
| Baxter International Inc (BAX) | $8.73 Billion | 12.63% | 1.29x | $9.94 Billion |
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simpl… Read more